Furthermore, by considering only individuals with JAK2 mutation to be cases in some of our analyses, we reduced the possibly of outcome misclassification if one were to assume that persons with the mutation experience exposures that already placed them on pathway towards developing clinical MPN. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.